Eastgate Biotech Corp (ETBI) 0.0140 $ETBI Eastg
Post# of 273242
Posted On: 09/14/2016 5:07:11 PM
Eastgate Biotech Corp (ETBI) 0.0140 $ETBI
Eastgate Biotech Announces That it Has Received a Substantial Order for Glucora, Its Natural Glucose Management Product
GlobeNewswire - Thu May 05, 7:00AM CDT
West Caldwell, NJ and Toronto, May 2, 2016 (GlobeNewswire/-) EastGate Biotech Corp. (PinkSheets: ETBI), an emerging pharmaceutical company aimed at utilizing drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules has announced that it has received a large order for Glucora, its natural glucose management product.
EastGate Biotech Receives Notice of Publication From the US Patent and Trademark Office for Two Patents for the Company's Proprietary Intraoral Lorazepam Spray
Marketwired - Tue Jan 19, 8:30AM CST
EastGate Biotech Corp. (OTC PINK: ETBI), an emerging pharmaceutical company aimed at utilizing drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules has received the notice of publication from the US Patent and Trademark Office for two patents for the company's intraoral Lorazepam Spray.
Eastgate Biotech Receives Repeat Purchase Order From Its Canadian Distributor
Marketwired - Wed Jan 06, 8:30AM CST
EastGate Biotech Corp. (OTC PINK: ETBI), an emerging pharmaceutical company aimed at utilizing drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules has received a repeat purchase order from its Canadian distributor Preferred Nutrition (www.pno.ca). As per the agreed upon sales terms the company has received a cash deposit for this order.
EastGate Biotech Announces the Commencement of Scale-Up Manufacturing Activities for Its Proprietary Intraoral Insulin Tablet
Marketwired - Tue Sep 29, 8:30AM CDT
EastGate Biotech Corp. (OTC PINK: ETBI), an emerging pharmaceutical company aimed at utilizing drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules, has announced that it has commenced scale-up activities for its proprietary intraoral insulin tablet.
EastGate Biotech Creates an Online Directory as a Marketing Tool for Its Nutraceutical Product
Marketwired - Thu Sep 24, 8:30AM CDT
EastGate Biotech Corp. (OTC PINK: ETBI), an emerging pharmaceutical company aimed at utilizing drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules created an online directory for stores carrying E-drops, marketed as UTI drops by our Canadian distributor, Preferred Nutrition Inc. (www.pno.ca).
EastGate Biotech Announces That Its Research Collaborator, the University of Guelph, Department of Molecular and Cellular Biology Receives NSERC Grant
Marketwired - Tue Jul 07, 8:30AM CDT
EastGate Biotech Corp. (OTC PINK: ETBI), an emerging pharmaceutical company aimed at utilizing drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules, has announced that its research collaborator, the University of Guelph, Department of Molecular and Cellular Biology received a grant from the National Sciences and Engineering Research Council of Canada (NSERC). The grant was approved for the development and evaluation of new nano delivery vehicles for natural antimicrobial products with improved efficacy..
EastGate Biotech Announces That Impex Healthcare Will Distribute One of Its Products, Glucora
Marketwired - Tue Jun 09, 8:30AM CDT
EastGate Biotech Corp. (OTC PINK: ETBI), an emerging pharmaceutical company aimed at utilizing drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules, has announced that Impex Healthcare (www.ImpexHealthcare.com) will commence the distribution and marketing of one of the company's natural products, Glucora, in Bangladesh along with future distribution of other glucose management products.
EastGate Biotech Announces Collaboration With the University of Guelph, Department of Molecular and Cellular Biology, for Its Natural Antibacterial Products
Marketwired - Thu May 28, 8:30AM CDT
EastGate Biotech Corp. (OTC PINK: ETBI), an emerging pharmaceutical company aimed at utilizing drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules, has announced today its collaboration with the University of Guelph, Department of Molecular and Cellular Biology. The collaboration involves evaluation of the antimicrobial activity of the company's natural antibacterial products, Cleanezze(TM) and VClean(TM).
EastGate Biotech Announces That PharmaCenter Ltd. Will Commence Marketing the Company's Nutraceutical Products
Marketwired - Tue May 26, 10:15AM CDT
EastGate Biotech Corp. (OTCBB: ETBI), an emerging pharmaceutical company aimed at utilizing drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules, has announced that PharmaCenter (www.PharmaCenter.sk or www.PharmaCenter.hu) will commence marketing E-drops, one of the company's nutraceutical products in Slovakia and Czech Republic.
EastGate Biotech Receives Purchase Order from its Canadian Distributor for Nutraceutical Products
PR Newswire - Wed Mar 11, 8:30AM CDT
EastGate Biotech Corp. (OTCBB: ETBI), an emerging pharmaceutical company aimed at utilizing drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules has received a purchase order from its newly-engaged Canadian distributor Preferred Nutrition (www.pno.ca). The company has already received a cash deposit for this initial order.
EastGate Biotech Provides Update On Its Patent Portfolio
PR Newswire - Tue Feb 03, 8:30AM CST
EastGate Biotech Corp. (OTCBB: ETBI), an emerging pharmaceutical company exploring drug delivery innovations for the development of novel formulations and alternative dosage forms of existing biologically active molecules provides update on its patent portfolio for its sub-micron self-nanoemulsifying platform technology.
EastGate Biotech Corp. Receives An NPN (Natural Product Number) For Its Product Glucora, Designed To Support Healthy Glucose Metabolism
PR Newswire - Fri Jan 23, 8:30AM CST
EastGate Biotech Corp. (OTCBB: ETBI), an emerging pharmaceutical company exploring drug delivery innovations for the development of novel formulations and alternative dosage forms of existing biologically active molecules receives an NPN (Natural Product Number) from the Natural and Non-Prescription Health Products Directorate of Health Canada for its natural product Glucora.
EastGate Acquisitions Announces Name Change To EastGate Biotech Corp. And New Stock Symbol
PR Newswire - Mon Dec 15, 8:30AM CST
EastGate Biotech Corp., formerly EastGate Acquisitions Corporation (OTCBB: ESAQ), an emerging pharmaceutical company exploring drug delivery innovations for the development of novel formulations and alternative dosage forms of existing biologically active molecules, announced today that the Financial Industry Regulatory Authority ("FINRA"
approved the company's change of corporate name to EastGate Biotech Corp. from EastGate Acquisitions Corporation . The Company's new trading symbol "ETBI" is now effective.
Eastgate Biotech Announces That it Has Received a Substantial Order for Glucora, Its Natural Glucose Management Product
GlobeNewswire - Thu May 05, 7:00AM CDT
West Caldwell, NJ and Toronto, May 2, 2016 (GlobeNewswire/-) EastGate Biotech Corp. (PinkSheets: ETBI), an emerging pharmaceutical company aimed at utilizing drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules has announced that it has received a large order for Glucora, its natural glucose management product.
EastGate Biotech Receives Notice of Publication From the US Patent and Trademark Office for Two Patents for the Company's Proprietary Intraoral Lorazepam Spray
Marketwired - Tue Jan 19, 8:30AM CST
EastGate Biotech Corp. (OTC PINK: ETBI), an emerging pharmaceutical company aimed at utilizing drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules has received the notice of publication from the US Patent and Trademark Office for two patents for the company's intraoral Lorazepam Spray.
Eastgate Biotech Receives Repeat Purchase Order From Its Canadian Distributor
Marketwired - Wed Jan 06, 8:30AM CST
EastGate Biotech Corp. (OTC PINK: ETBI), an emerging pharmaceutical company aimed at utilizing drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules has received a repeat purchase order from its Canadian distributor Preferred Nutrition (www.pno.ca). As per the agreed upon sales terms the company has received a cash deposit for this order.
EastGate Biotech Announces the Commencement of Scale-Up Manufacturing Activities for Its Proprietary Intraoral Insulin Tablet
Marketwired - Tue Sep 29, 8:30AM CDT
EastGate Biotech Corp. (OTC PINK: ETBI), an emerging pharmaceutical company aimed at utilizing drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules, has announced that it has commenced scale-up activities for its proprietary intraoral insulin tablet.
EastGate Biotech Creates an Online Directory as a Marketing Tool for Its Nutraceutical Product
Marketwired - Thu Sep 24, 8:30AM CDT
EastGate Biotech Corp. (OTC PINK: ETBI), an emerging pharmaceutical company aimed at utilizing drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules created an online directory for stores carrying E-drops, marketed as UTI drops by our Canadian distributor, Preferred Nutrition Inc. (www.pno.ca).
EastGate Biotech Announces That Its Research Collaborator, the University of Guelph, Department of Molecular and Cellular Biology Receives NSERC Grant
Marketwired - Tue Jul 07, 8:30AM CDT
EastGate Biotech Corp. (OTC PINK: ETBI), an emerging pharmaceutical company aimed at utilizing drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules, has announced that its research collaborator, the University of Guelph, Department of Molecular and Cellular Biology received a grant from the National Sciences and Engineering Research Council of Canada (NSERC). The grant was approved for the development and evaluation of new nano delivery vehicles for natural antimicrobial products with improved efficacy..
EastGate Biotech Announces That Impex Healthcare Will Distribute One of Its Products, Glucora
Marketwired - Tue Jun 09, 8:30AM CDT
EastGate Biotech Corp. (OTC PINK: ETBI), an emerging pharmaceutical company aimed at utilizing drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules, has announced that Impex Healthcare (www.ImpexHealthcare.com) will commence the distribution and marketing of one of the company's natural products, Glucora, in Bangladesh along with future distribution of other glucose management products.
EastGate Biotech Announces Collaboration With the University of Guelph, Department of Molecular and Cellular Biology, for Its Natural Antibacterial Products
Marketwired - Thu May 28, 8:30AM CDT
EastGate Biotech Corp. (OTC PINK: ETBI), an emerging pharmaceutical company aimed at utilizing drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules, has announced today its collaboration with the University of Guelph, Department of Molecular and Cellular Biology. The collaboration involves evaluation of the antimicrobial activity of the company's natural antibacterial products, Cleanezze(TM) and VClean(TM).
EastGate Biotech Announces That PharmaCenter Ltd. Will Commence Marketing the Company's Nutraceutical Products
Marketwired - Tue May 26, 10:15AM CDT
EastGate Biotech Corp. (OTCBB: ETBI), an emerging pharmaceutical company aimed at utilizing drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules, has announced that PharmaCenter (www.PharmaCenter.sk or www.PharmaCenter.hu) will commence marketing E-drops, one of the company's nutraceutical products in Slovakia and Czech Republic.
EastGate Biotech Receives Purchase Order from its Canadian Distributor for Nutraceutical Products
PR Newswire - Wed Mar 11, 8:30AM CDT
EastGate Biotech Corp. (OTCBB: ETBI), an emerging pharmaceutical company aimed at utilizing drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules has received a purchase order from its newly-engaged Canadian distributor Preferred Nutrition (www.pno.ca). The company has already received a cash deposit for this initial order.
EastGate Biotech Provides Update On Its Patent Portfolio
PR Newswire - Tue Feb 03, 8:30AM CST
EastGate Biotech Corp. (OTCBB: ETBI), an emerging pharmaceutical company exploring drug delivery innovations for the development of novel formulations and alternative dosage forms of existing biologically active molecules provides update on its patent portfolio for its sub-micron self-nanoemulsifying platform technology.
EastGate Biotech Corp. Receives An NPN (Natural Product Number) For Its Product Glucora, Designed To Support Healthy Glucose Metabolism
PR Newswire - Fri Jan 23, 8:30AM CST
EastGate Biotech Corp. (OTCBB: ETBI), an emerging pharmaceutical company exploring drug delivery innovations for the development of novel formulations and alternative dosage forms of existing biologically active molecules receives an NPN (Natural Product Number) from the Natural and Non-Prescription Health Products Directorate of Health Canada for its natural product Glucora.
EastGate Acquisitions Announces Name Change To EastGate Biotech Corp. And New Stock Symbol
PR Newswire - Mon Dec 15, 8:30AM CST
EastGate Biotech Corp., formerly EastGate Acquisitions Corporation (OTCBB: ESAQ), an emerging pharmaceutical company exploring drug delivery innovations for the development of novel formulations and alternative dosage forms of existing biologically active molecules, announced today that the Financial Industry Regulatory Authority ("FINRA"
approved the company's change of corporate name to EastGate Biotech Corp. from EastGate Acquisitions Corporation . The Company's new trading symbol "ETBI" is now effective. 
(0)
(0)Scroll down for more posts ▼